E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Chronic Obstructive Pulmonary Disease (COPD) which may be called emphysema or chronic bronchitis. |
|
E.1.1.1 | Medical condition in easily understood language |
Chronic Obstructive Pulmonary Disease (COPD) COPD is a condition that affects the lungs. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Respiratory Tract Diseases [C08] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10010952 |
E.1.2 | Term | COPD |
E.1.2 | System Organ Class | 100000004855 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To compare the effectiveness of TRELEGY ELLIPTA with non-ELLIPTA
MITT for the impact of COPD on wellbeing and daily life after 24 weeks’ treatment. |
|
E.2.2 | Secondary objectives of the trial |
Secondary:
- To compare the effectiveness of TRELEGY ELLIPTA with non-ELLIPTA MITT on lung function after 24 weeks’ treatment.
- To compare critical errors (CE) made by study participants using the ELLIPTA device with participants using selected non- ELLIPTA MITT after 24 weeks’ treatment.
Other:
- To compare TRELEGY ELLIPTA with inhaled non-ELLIPTA MITT for a clinically important deterioration (CID)
-To quantify the incidence, rate and time to first moderate/severe COPD exacerbation for study participants on TRELEGY ELLIPTA compared with participants on non-ELLIPTA MITT.
-To compare the effectiveness of TRELEGY ELLIPTA with non-ELLIPTA MITT for COPD-related Healthcare Resource Utilisation (HCRU).
Exploratory:
-To assess the data for correlation between critical errors and clinical outcomes
-To describe the patient study experience
Safety:
-To compare safety for study participants using the ELLIPTA device with participants using non-ELLIPTA MITT after 24 weeks’ treatment. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Participants are eligible to be included in the study only if all of the following criteria apply:
1. Informed Consent: Capable of giving signed informed consent as described in Appendix 2 of study protocol which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
2. COPD Diagnosis: Patients with a documented physician diagnosis of COPD.
3. Severity of COPD symptoms: A score of ≥10 on the COPD Assessment Test (CAT) at screening.
4. History of Exacerbations. Patients who have a history of treatment with systemic/oral corticosteroids, antibiotics and/or hospitalisation for at least one COPD exacerbation in the 3 years prior to randomisation. This will be captured through patient recall and/or medical records and must be documented in patients notes.
Prior use of systemic/oral corticosteroids and/or antibiotics alone does not qualify as an exacerbation history unless the use was associated with treatment of worsening symptoms of COPD.
5. Existing COPD Maintenance Treatment. Patients currently receiving one of the non-ELLIPTA maintenance therapies listed below who have been prescribed it continually for at least 16 weeks prior to randomisation.
Continuous prescription is defined as a minimum of 60 days’ prescription cover during the prior 16 weeks.
The non -ELLIPTA maintenance therapy must be one of the following
- ICS in combination with LAMA and LABA (MITT)
- LAMA and LABA used in combination as a dual therapy
- LABA and ICS used in combination as a dual therapy
NOTE: patients who are currently on a dual maintenance therapy for COPD must be considered by their physician to require a step- up to triple therapy. The reason for the physician decision to step- up must be documented.
Patients who are receiving only COPD medication on an ‘as required’ basis are not eligible.
6. Age and Sex: participants must be aged ≥ 40 years of age at the time of signing the informed consent. |
|
E.4 | Principal exclusion criteria |
Participants are excluded from the study if any of the following criteria apply:
1. Women of child bearing potential. as defined in Appendix 4 of study protocol. This includes women who are pregnant or lactating or are planning on becoming pregnant during the study.
2. Medical Conditions: Patients with any life-threatening condition i.e. low probability, in the opinion of the investigator, of 6-month survival due to severity of COPD or comorbid condition.
3. Patients with unstable COPD. Patients with resolution of an exacerbation less than 2 weeks prior to visit 1, must not be randomised. Patients may be rescreened 2 weeks after resolution of exacerbation (exacerbation is defined by treatment with systemic
corticosteroids and/or antibiotic).
4. Other diseases/abnormalities: patients with historical or current evidence of uncontrolled or clinically significant disease. Significant is defined as any disease that, in the opinion of the investigator, would put the safety of the participant at risk through participation, or which would affect the effectiveness or safety analysis if the
disease/condition exacerbated during the study
5. Hypersensitivity: A history of allergy or hypersensitivity to any corticosteroid, anticholinergic/muscarinic receptor antagonist, β2-agonist, lactose/milk protein or magnesium stearate or a medical condition such as narrow-angle glaucoma, prostatic hypertrophy or bladder neck obstruction that, in the opinion of the investigator
contraindicates study participation.
6. Prior/Concomitant Therapy with Oral Corticosteroid Patients who, in the opinion of the treating investigator, are chronic users of oral
corticosteroids for respiratory or other indications (if unsure discuss with the medical monitor prior to screening).
Chronic use is defined as more than 14 days continuous use during the 12 weeks prior to visit 1.
7. Participants currently participating in any interventional clinical study.
Participants taking any investigational drug treatment within 30 days prior to Visit 1 or within five half-lives (t½) of the prior investigational study (whichever is the longer of the two). |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Proportion of responders based on the COPD Assessment Test (CAT) at week 24. Response defined as change from baseline of CAT score ≥ 2 at 24 weeks. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
1. Change from baseline in Forced Expiratory Volume in one second (FEV1) at 24 weeks (subgroup of patients).
2. Percentage of participants making at least 1 critical error in inhalation technique at the 24-week visit. (subgroup of patients).
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
The primary purpose of this study is to meet this need by assessing the effectiveness of TRELEGY ELLIPTA relative to non-ELLIPTA MITT within the usual clinical practice setting |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 20 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 147 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Canada |
Germany |
Netherlands |
Spain |
Sweden |
United Kingdom |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 2 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 2 |
E.8.9.2 | In all countries concerned by the trial days | 0 |